Angiogenesi
Gli inibitori dell'angiogenesi sono composti che interferiscono con la formazione di nuovi vasi sanguigni, un processo cruciale nella crescita e metastasi del cancro. Inibendo l'angiogenesi, questi composti possono limitare l'apporto di sangue ai tumori, rallentandone o arrestando la crescita. Gli inibitori dell'angiogenesi sono fondamentali nella ricerca sul cancro e nello sviluppo terapeutico, offrendo approfondimenti sui meccanismi di progressione tumorale e potenziali trattamenti per il cancro e altre malattie legate all'angiogenesi. Presso CymitQuimica, offriamo un'ampia gamma di inibitori dell'angiogenesi di alta qualità per supportare le tue ricerche in oncologia e biologia vascolare.
Sottocategorie di "Angiogenesi"
- BTK(158 prodotti)
- Bcr-Abl(113 prodotti)
- EGFR(598 prodotti)
- FAK(72 prodotti)
- FLT(90 prodotti)
- Recettore del fattore di crescita dei fibroblasti (FGFR)(182 prodotti)
- JAK(246 prodotti)
- PDGFR(126 prodotti)
- RAAS(90 prodotti)
- Src(81 prodotti)
- Syk(37 prodotti)
- Trombina(53 prodotti)
- VDA(2 prodotti)
- VEGFR(250 prodotti)
Mostrare 6 più sottocategorie
Trovati 2040 prodotti di "Angiogenesi"
Ordinare per
Purezza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3K/VEGFR2-IN-1
CAS:PI3K/VEGFR2-IN-1 is a potent dual inhibitor targeting both PI3K and VEGFR2 with IC50 values of 2.21 μM for PI3K and 68 μM for VEGFR2, respectively.Formula:C17H14ClN3OSPurezza:98%Colore e forma:SolidPeso molecolare:343.83EGFR-IN-29
CAS:EGFR-IN-29 is a potent EGFR inhibitor.Formula:C36H46BrN8O2PColore e forma:SolidPeso molecolare:733.68Lepzacitinib
CAS:Lepzacitinib is a selective, inflammatory, small molecule JAK1/3(Janus kinase) inhibitor primarily used for the treatment of atopic dermatitis.Formula:C18H21N5O3Purezza:99.85%Colore e forma:SolidPeso molecolare:355.39EGFR-IN-32
CAS:EGFR-IN-32, a potent EGFR blocker, shows promise for EGFR-mutated illnesses. (Patent WO2021185297A1, compound 2)Formula:C31H34N6O3Colore e forma:SolidPeso molecolare:538.64Irpagratinib
CAS:<p>Irpagratinib (ABSK011) is an FGFR4 antagonist with anticancer activity, inhibiting FGFR4 autophosphorylation and blocking downstream signaling pathways.</p>Formula:C28H32F2N6O5Purezza:99.08% - 99.38%Colore e forma:SolidPeso molecolare:570.59BTK-IN-18
CAS:BTK-IN-18 is a potent, reversible inhibitor of Bruton's tyrosine kinase (BTK) with an inhibitory concentration (IC50) of 0.002 µM.Formula:C20H22Cl2N6OColore e forma:SolidPeso molecolare:433.33Atiprimod dimaleate
CAS:Atiprimod Dimaleate is a JAK2 inhibitor.Formula:C30H52N2O8Colore e forma:SolidPeso molecolare:568.74AT-9283 L-lactate
CAS:<p>AT-9283 L-lactate is an inhibitor of aurora kinase.</p>Formula:C22H29N7O5Purezza:98%Colore e forma:SolidPeso molecolare:471.52EGFR-IN-61
CAS:EGFR-IN-61 inhibits EGFR kinase (IC50: 42 nM L858R/T790M, 137 nM L858R/T790M/C797S, 743 nM WT) and slows A549 & H1975 cell growth (IC50: 2.14 & 1.82 μM).Formula:C33H37ClN8O3Purezza:98%Colore e forma:SolidPeso molecolare:629.15VEGFR2-IN-3
CAS:VEGFR2-IN-3 (compound 385) is a potent inhibitor of VEGFR2 [1].Formula:C26H28ClN5O4Purezza:98%Colore e forma:SolidPeso molecolare:509.98Nezulcitinib
CAS:Nezulcitinib (TD-0903) is an inhaled pan-JAK inhibitor targeting COVID-19-related acute lung injury.Formula:C30H37N7O2Colore e forma:SolidPeso molecolare:527.66TG 100572 Hydrochloride
CAS:<p>TG 100572 Hydrochloride is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.</p>Formula:C26H27Cl2N5O2Purezza:98%Colore e forma:SolidPeso molecolare:512.43TIE-2/VEGFR-2 kinase-IN-4
CAS:<p>TIE-2/VEGFR-2 kinase-IN-4, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting inhibitory</p>Formula:C26H17F4N5O4Colore e forma:SolidPeso molecolare:539.44ALK/EGFR-IN-1
CAS:ALK/EGFR-IN-1 (Compound 8l) is a dual inhibitor targeting both ALK and EGFR, effectively blocking their phosphorylation.Formula:C27H34ClN7O3SPurezza:98%Colore e forma:SolidPeso molecolare:572.12CCT365623 hydrochloride
CAS:CCT365623 hydrochloride is an orally active inhibitor of lysyl oxidase (LOX) (IC50: 0.89 μM). It suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF.Formula:C18H18ClNO4S3Purezza:98%Colore e forma:SolidPeso molecolare:443.99CT-721
CAS:CT-721: potent, time-bound Bcr-Abl inhibitor, IC50 21.3 nM, effective against CML.Formula:C30H29ClN6OPurezza:98%Colore e forma:SolidPeso molecolare:525.04(Z)-RG-13022
CAS:<p>(Z)-RG-13022 is a tyrosine kinase (TK) inhibitor that preferentially inhibits the TK activity of the EGF receptor, restricting the EGF-stimulated growth of cultured cells. It demonstrates an IC50 of 11 μM for DNA synthesis in HN5 cells, showcasing thrice the potency of its isomer, (E)-RG-13022 (IC50 = 38 μM). This compound is applied in breast cancer cell research [1] [2].</p>Formula:C16H14N2O2Colore e forma:SolidPeso molecolare:266.29BEBT-109
CAS:BEBT-109 is a selective epidermal growth factor receptor (EGFR) inhibitor that shows anti-tumor activity in EGFR-mutant non-small cell lung cancer.Formula:C27H32N8O3Purezza:97.26%Colore e forma:SolidPeso molecolare:516.6PF-06459988
CAS:PF-06459988 is a novel, effective, orally active, irreversible, and selective epidermal growth factor receptor (EGFR) mutant inhibitor.Formula:C19H22ClN7O3Purezza:98%Colore e forma:SolidPeso molecolare:431.88TL02-59
CAS:TL02-59: Fgr inhibitor (IC50=0.03nM), also targets Lyn (0.1nM), Hck (160nM), halts acute myelogenous leukemia growth.Formula:C32H34F3N5O4Purezza:98.77%Colore e forma:SolidPeso molecolare:609.64EGFR-IN-33
CAS:<p>EGFR-IN-33, a low-toxicity acrylamide, inhibits EGFR, aiding against cancer, especially NSCLC (from WO2021185348A1, comp. 13).</p>Formula:C26H25ClN6O2Colore e forma:SolidPeso molecolare:488.97PAT-505
CAS:PAT-505 is an autologous epidermal growth factor inhibitor.Formula:C23H18ClF2N3O2SPurezza:98.84%Colore e forma:SolidPeso molecolare:473.92Larixol
CAS:Larixol acts as both an fMLP inhibitor and a modulator of various signaling pathways by inhibiting Src kinase, ERK1/2, p38, and AKT phosphorylation critical forFormula:C20H34O2Purezza:98%Colore e forma:SolidPeso molecolare:306.48Ruxolitinib sulfate
CAS:Ruxolitinib sulfate, a potent JAK1/2 inhibitor (IC50: 3.3/2.8 nM), is >130x more selective for JAK1/2 than JAK3.Formula:C17H20N6O4SColore e forma:SolidPeso molecolare:404.45JAK-IN-4
CAS:JAK-IN-4 is a prodrug of a JAK inhibitor, effective in murine collagen induced arthritis model.Formula:C18H21N4Na2O6PPurezza:98%Colore e forma:SolidPeso molecolare:466.341ALK/ROS1-IN-1
CAS:ALK/ROS1-IN-1 is a potent and selective anti-crizotinib-resistant ALK/ROS1 dual inhibitor (IC50s: 0.530 μM and 0.174 μM for ROS1 and ALK enzyme).Formula:C30H35F3N6O3Purezza:98%Colore e forma:SolidPeso molecolare:584.63FLT3-IN-14
CAS:FLT3-IN-14: FLT3 inhibitor; FLT3-WT IC50=5.6nM, FLT3-ITD IC50=1.4nM; blocks Y591 phosphorylation; G1 arrest; pro-apoptotic.Formula:C25H24N6O2SColore e forma:SolidPeso molecolare:472.56BTK-IN-17
BTK-IN-17: selective, oral BTK inhibitor, IC50=13.7 nM, reduces p-BTK Y223/p-PLCγ2 Y1217, anti-inflammatory.Formula:C26H23N7O2Colore e forma:SolidPeso molecolare:465.51Atiprimod dihydrochloride
CAS:JAK2 inhibitor; IC50=397 nM; hampers STAT3/5 phosphorylation; curbs growth and triggers apoptosis in JAK2V617F+ cells.Formula:C22H46Cl2N2Colore e forma:SolidPeso molecolare:409.52Resigratinib
CAS:Resigratinib (KIN-3248) is an oral, irreversible pan-FGFR family protein inhibitor, covalently binds to and inhibits all four FGFR isoforms(FGFR1/2/3/4).Formula:C26H27F2N7O3Purezza:98.58%Colore e forma:SolidPeso molecolare:523.53DosatiLink-2
CAS:DosatiLink-2 is an inhibitor of the Abelson murine leukemia (ABL) enzyme [1].Formula:C65H85Cl2F2N13O15SColore e forma:SolidPeso molecolare:1429.4215-deoxy-Δ12,14-Prostaglandin D2
CAS:15-deoxy-Δ12,14-Prostaglandin D2 (15-deoxy-Δ12,14-PGD2) is a PGD2 metabolite functioning as an agonist for the PGD2 receptor 2 (DP2), with a binding affinity (Ki) of 50 nM for the mouse DP2 receptor expressed in HEK293 cell membranes. It activates eosinophils with an EC50 of 8 nM and enhances the recruitment of steroid receptor coactivator-1 (SRC-1) to peroxisome proliferator-activated receptor γ (PPARγ), initiating PPARγ-mediated transcription at 5 µM concentration. Furthermore, it exhibits cytotoxicity towards L1210 murine leukemia cells with an IC50 of 0.3 µg/ml and displays weaker inhibition of ADP-induced platelet aggregation than PGD2, with an IC50 of 320 ng/ml.Formula:C20H30O4Colore e forma:SolidPeso molecolare:334.456JAK-IN-17
"JAK-IN-17: Potent JAK inhibitor for studying ocular, skin, and respiratory diseases."Formula:C33H38F2N6O8Colore e forma:SolidPeso molecolare:684.69Brolucizumab
CAS:Brolucizumab (anti-VEGF-A scFv) potently blocks VEGF-A to reduce neovascularization in wet AMD, with picomolar binding affinity.Purezza:95%Colore e forma:LiquidT338C Src-IN-1
CAS:T338C Src-IN-1 is a potent mutant-Src T338C inhibitor(T338C,IC50=111 nM relative to WT c-Src (10-fold increase)).Formula:C17H20N6O2SPurezza:98%Colore e forma:SolidPeso molecolare:372.44JAK-IN-24
CAS:JAK-IN-24: JAK inhibitor, IC50: 0.534 nM (4 μM ATP), 24 nM (1mM ATP), STAT5 phosphorylation IC50: 86.171 nM.Formula:C20H25N5O2Colore e forma:SolidPeso molecolare:367.44UNC5293
CAS:UNC5293: potent oral MERTK inhibitor, Ki=190 pM, IC50=0.9 nM; selective vs Axl/Tyro3/Flt3; good mouse PK; used in leukemia research.Formula:C30H42N6O2Colore e forma:SolidPeso molecolare:518.69VEGFR-2-IN-9
CAS:VEGFR-2-IN-9 (KDR-in-4) is a potent KDR/VEGFR2 inhibitor (IC50: 7 nM). It can be used to study breast cancer.Formula:C23H25N3O3Purezza:97.19%Colore e forma:SolidPeso molecolare:391.46TIE-2/VEGFR-2 kinase-IN-3
CAS:TIE-2/VEGFR-2 kinase-IN-3, a benzimidazole derivative, serves as a potent inhibitor of the tyrosine kinase receptors TIE-2 and VEGFR-2, exhibiting IC50 valuesFormula:C23H17F4N5O3SColore e forma:SolidPeso molecolare:519.47JAK-IN-25
CAS:JAK-IN-25 (compound 19), a potent JAK inhibitor, exhibits IC50 values of 6 nM for TYK2, 21 nM for JAK1, 8 nM for JAK2, and 1051 nM for JAK3.Formula:C19H17N5O4Purezza:98%Colore e forma:SolidPeso molecolare:379.37Tyrphostin AG1433
CAS:Tyrphostin AG1433 (AG1433) is an inhibitor of tyrosine kinases and also a dual inhibitor of PDGFRβ(IC50s = 5.0 μM) and VEGFR-2 (Flk-1/KDR)(IC50s = 9.3 μM).Formula:C16H14N2O2Purezza:98.47%Colore e forma:SolidPeso molecolare:266.29Upadacitinib tartrate
CAS:Upadacitinib: potent, selective JAK1 inhibitor, 74x preferential to JAK2, effective in rat arthritis.Formula:C21H33F3N6O11Purezza:98%Colore e forma:SolidPeso molecolare:602.521CP-547632 TFA
CAS:CP-547632 TFA, an oral VEGFR-2 and FGF inhibitor, IC50: VEGFR-2 at 11 nM, FGF at 9 nM, shows antitumor activity.Formula:C22H25BrF5N5O5SPurezza:98%Colore e forma:SolidPeso molecolare:646.43Tubulin/JAK2-IN-1
CAS:Tubulin/JAK2-IN-1 (compound 7g) serves as a potent dual inhibitor targeting both Janus kinase 2 (JAK2) and microtubules, demonstrating significantFormula:C22H20N6O3Colore e forma:SolidPeso molecolare:416.43Pivanex
CAS:Pivanex, an oral HDAC inhibitor, targets metastasis, angiogenesis, reduces Bcr-Abl protein, and promotes apoptosis.Formula:C10H18O4Purezza:≥98%Colore e forma:SolidPeso molecolare:202.25HIF-2α-IN-1
CAS:HIF-2α-IN-1 is a potent HIF-2α inhibitor with IC50 values less than 500 nM.Formula:C16H8F5NO4SPurezza:97.99%Colore e forma:SolidPeso molecolare:405.3JAK-IN-1
CAS:JAK-IN-1 shows improved selectivity for JAK3 over JAK1. JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively.Formula:C20H24N6O2Purezza:98%Colore e forma:SolidPeso molecolare:380.44ALK-IN-6
CAS:ALK-IN-6 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK, IC50s: 71 nM, 18.72 nM, and 36.81 nM for ALK wild, ALK F1196M and ALK F1174L).Formula:C26H29ClD3N5O3SPurezza:98%Colore e forma:SolidPeso molecolare:533.1BTK inhibitor 20
CAS:BTK inhibitor 20 is a potent BTK inhibitor with an IC 50 of 8 nM .Formula:C37H42N8O4Colore e forma:SolidPeso molecolare:662.78DDa-1
CAS:DDa-1 is a potent (kinase degrader) [1].Formula:C60H77Cl2N13O3SColore e forma:SoildPeso molecolare:1131.31EGFR-IN-74
EGFR-IN-74 is a potent inhibitor targeting EGFR, specifically effective against the L858R/T790M mutations, exhibiting an IC50 value of 138 nM.Formula:C32H28BrF3N6O4SColore e forma:SolidPeso molecolare:729.57EGFR/HER2-IN-13
CAS:EGFR/HER2-IN-13 (Compd 38) serves as an inhibitor targeting mutant EGFR/HER2s that show resistance to existing drugs. It is primarily utilized in cancer research.Formula:C27H36N8O3Peso molecolare:520.63JND3229
CAS:JND3229 inhibits EGFRC797S; IC50: 5.8-30.5 nM; halts cell growth; effective in non-small cell lung cancer study.Formula:C33H41ClN8O2Purezza:98.75%Colore e forma:SolidPeso molecolare:617.18Edralbrutinib
CAS:Edralbrutinib (TG-1701) is a potent BTK inhibitor with anticancer activity and is used in the treatment of tumors, immune system disorders, and blood andFormula:C26H21F2N5O3Purezza:99.41%Colore e forma:SolidPeso molecolare:489.47EGFR-IN-87
CAS:EGFR-IN-87 is an EGFR tyrosine kinase inhibitor with potent inhibitory activity, exhibiting IC50 values of 3.1 nM, 1.3 nM, and 7.1 nM against EGFR_d746-750,Formula:C28H33N7O2Purezza:98.64%Colore e forma:SolidPeso molecolare:499.61Zongertinib
CAS:Zongertinib is a human HER2-selective tyrosine kinase inhibitor, a novel TK that is highly selective for covalent binding to the HER2 tyrosine kinase domain (Formula:C29H29N9O2Purezza:98.24%Colore e forma:SolidPeso molecolare:535.6TAK-020
CAS:TAK-020 is a potent covalent inhibitor of Btk with potential antitumor activity for the study of rheumatoid arthritis and immune-related diseases.Formula:C18H17N5O3Purezza:98.66%Colore e forma:SolidPeso molecolare:351.36BMS-935177
CAS:BMS-935177 is a reversible BTK inhibitor with IC50 value of 3 nM.Formula:C31H26N4O3Purezza:99.89%Colore e forma:SolidPeso molecolare:502.56ALK-IN-27
CAS:Neladalkib (NVL-655) is an ALK inhibitor with antitumor activity for the study of non-small cell cancers.Formula:C23H22ClFN6OPurezza:99.71%Colore e forma:SolidPeso molecolare:452.91EGFR-IN-1 hydrochloride
CAS:EGFR-IN-1 HCl targets L858R/T790M EGFR mutants over wild-type; IC50: 4 nM in H1975, 28 nM in mutant HCC827 cells.Formula:C28H31ClN6O4Purezza:99.16%Colore e forma:SolidPeso molecolare:551.04CH6953755
CAS:CH6953755: oral YES1 kinase inhibitor, IC50 1.8 nM, potent, selective, anticancer, halts cell proliferation.Formula:C26H22F2N6O4SPurezza:98.87%Colore e forma:SolidPeso molecolare:552.55KER047
CAS:ALK2-IN-4, a highly effective ALK2 inhibitor.Formula:C26H30FN7OPurezza:98.49% - >99.99%Colore e forma:SolidPeso molecolare:475.56Sevabertinib
CAS:Sevabertinib (BAY 2927088) is an EGFR tyrosine kinase inhibitor, with anticancer activity, used in research on non-small cell lung cancer.Formula:C24H25ClN4O5Purezza:99.81%Colore e forma:SolidPeso molecolare:484.93IN-1130
CAS:IN-1130: ALK5 inhibitor, IC50 - 5.3 nM (Smad3), 36 nM (casein), 4.3 μM (p38α MAPK).Formula:C25H20N6OPurezza:99.79%Colore e forma:SolidPeso molecolare:420.47Ifebemtinib
CAS:Ifebemtinib (BI-853520) is an adhesion plaque kinase inhibitor with anti-tumour activity for the study of breast cancer.Formula:C28H28F4N6O4Purezza:98.84% - 99.85%Colore e forma:SolidPeso molecolare:588.55Src Inhibitor 3
CAS:Src Inhibitor 3 blocks c-Src kinase (IC50 <3 nM CSK HTRF, <4 nM Caliper), boosting T cell growth from receptor signals.Formula:C34H32ClFN8O4Purezza:98.35%Colore e forma:SolidPeso molecolare:671.12HM43239
CAS:HM43239: oral FLT3 inhibitor; IC50: FLT3 WT 1.1nM, ITD 1.8nM, D835Y 1.0nM; blocks p-STAT5/p-ERK; affects SYK, JAK1/2, TAK1; halts leukemia cell growth.Formula:C29H33ClN6Purezza:99.7%Colore e forma:SolidPeso molecolare:501.07Tyrosine kinase-IN-9
CAS:<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Formula:C20H14ClN3O3Colore e forma:SolidPeso molecolare:379.796TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Formula:C21H21NO4Colore e forma:SolidPeso molecolare:351.396lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Formula:C16H25N5OSColore e forma:SolidPeso molecolare:335.468LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Formula:C26H31N7O2Colore e forma:SolidPeso molecolare:473.57EGFR-IN-147
CAS:EGFR-IN-147 (compound ID-5841161) is a potent EGFR inhibitor, demonstrating a 14% inhibition rate at a concentration of 1μM. It holds promise for cancer research applications.Formula:C13H13N5OColore e forma:SolidPeso molecolare:255.275VEGFR-2-IN-65
CAS:VEGFR-2-IN-65 (Compound 07) functions as a VEGFR-2 inhibitor. It forms hydrogen bonds with Cys180 and can inhibit tube formation in HUVECs.Formula:C21H18N2O3Colore e forma:SolidPeso molecolare:346.379Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Formula:C20H20N4O2SColore e forma:SolidPeso molecolare:380.463DA-0157
CAS:<p>DA-0157 is an orally active inhibitor targeting EGFR and ALK, designed to overcome resistance mutations in non-small cell lung cancer (NSCLC). It effectively inhibits the proliferation of Ba/F3-EGFR Del19/T790M/C797S (IC50= 6.9 nM), Ba/F3-EGFR WT (IC50= 0.83 μM), Ba/F3-EML4-ALK-L1196M (IC50= 5.5 nM), and Ba/F3-EML4-ALK (IC50= 7.4 nM). Additionally, DA-0157 inhibits CYP2D6 with an IC50 of 5.26 μM and demonstrates antitumor activity in mouse models.</p>Formula:C31H43BrN7O2PColore e forma:SolidPeso molecolare:656.597FGFR1 inhibitor-16
CAS:FGFR1inhibitor-16 (Compound 89) functions as an FGFR1 inhibitor, demonstrating an inhibition rate of 53.00% at a concentration of 50 μM and 24.95% at 10 μM. It is utilized in tumor research.Formula:C16H9N5O3SColore e forma:SolidPeso molecolare:351.339FAK-IN-3
<p>FAK-IN-3 inhibits FAK, reduces PA-1 cell migration/invasion, and tumor growth, with no major side effects.</p>Formula:C28H28N6O4Colore e forma:SolidPeso molecolare:512.56FGFR4-IN-7
FGFR4-IN-7 is a covalent, reversible FGFR4 inhibitor (IC50: 0.42 μM) that blocks the FGFR4 signaling pathway, thereby inducing apoptosis.Formula:C26H25Cl2N5O3Colore e forma:SolidPeso molecolare:526.41VEGFR-2-IN-13
<p>VEGFR-2-IN-13 (Compound 19a) is a potent VEGFR-2 inhibitor (IC50: 3.4 nM). vEGFR-2-IN-13 arrests the HepG2 cell cycle in G2/M phase and induces apoptosis.</p>Formula:C24H18N6O2SColore e forma:SolidPeso molecolare:454.5EGFR-IN-44
EGFR-IN-44: potent EGFR kinase inhibitor, orally active, IC50 4.11 nM, 33.57% bioavailability, induces apoptosis, for lung cancer study.Formula:C27H29ClN6O2SColore e forma:SolidPeso molecolare:537.08DBMB
CAS:DBMB is a spleen tyrosine kinase (Syk) inhibitor that significantly suppresses Syk enzyme activity. It possesses anti-inflammatory properties by inhibiting NF-κB signaling, thereby reducing the production of inflammatory mediators such as nitric oxide (NO) and prostaglandin E2 (PGE2). DBMB can be utilized in research on inflammatory diseases.Formula:C24H22N4OColore e forma:SolidPeso molecolare:382.458BTK-IN-8
BTK-IN-8: potent, selective covalent BTK inhibitor; IC50=0.22 nM, Kd=0.91 nM; effective in blood CD69 cells (IC50=0.029 μM).Formula:C26H36N6O3Colore e forma:SolidPeso molecolare:480.6JBJ-02-112-05
CAS:JBJ-02-112-05 is a potent, mutant-selective, allosteric and orally active inhibitor of EGFR with an IC 50 of 15 nM for EGFR L858R/T790M [1].Formula:C27H20N4O2SPurezza:98%Colore e forma:SolidPeso molecolare:464.54EGFR-IN-38
CAS:EGFR-IN-38: low-toxic acrylamide-derived EGFR inhibitor, targets NSCLC, patented for research on EGFR mutation-related diseases.Formula:C25H24ClN7O2Colore e forma:SolidPeso molecolare:489.96Flonoltinib sulfate
CAS:Flonoltinib maleate is an orally active dual inhibitor of JAK2/FLT3, with IC50 values of 0.7 nM for JAK2, 4 nM for FLT3, 26 nM for JAK1, and 39 nM for JAK3. It exhibits anticancer properties.Formula:C25H36FN7O5SColore e forma:SolidPeso molecolare:565.661TX2-121-1
CAS:TX2-121-1 targets HER3 for proteasome-mediated degradation to inhibit HER3-dependent signalling and growth.Formula:C42H52N8O3Purezza:98%Colore e forma:SolidPeso molecolare:716.91CEP-14083
CAS:<p>CEP-14083: potent ALK inhibitor, effective in NPM/ALK T-cell lymphoma, binds ATP site; IC50=11 nmol/L, also inhibits insulin receptor, preclinical efficacy.</p>Formula:C31H30N6O2Colore e forma:SolidPeso molecolare:518.61E6201
CAS:E6201, a dual kinase inhibitor, blocks MEK1/FLT3 and has anti-tumor/psoriasis effects with low IC50s: ERK2 (5.2 nM), JNK (91 nM), p38 MAPK (19 nM).Formula:C21H27NO6Colore e forma:SolidPeso molecolare:389.44Paeoniflorin-6′-O-benzene sulfonate
CAS:Paeoniflorin-6′-O-benzene sulfonate (CP-25) acts as an inhibitor of G protein-coupled receptor kinase 2 (GRK2), preventing its translocation to the cell membrane and inhibiting the JAK1/STAT3 signaling pathway. It suppresses HaCaT cell proliferation induced by IL-17A/CXCL2. In mouse models, CP-25 reduces the levels of inflammatory cytokines and chemokines such as IL-17A, IL-17F, IFN-γ, TNF-α, IL-22, IL-23, CXCL2, CXCL3, and CXCL9, thereby alleviating psoriasis induced by Imiquimod.Formula:C29H32O13SColore e forma:SolidPeso molecolare:620.622SJ-C1044
CAS:<p>SJ-C1044 is an orally effective pan-RAF inhibitor demonstrating immunomodulatory and antitumor activities. It targets wild-type BRAF, wild-type CRAF, and BRAF(V600E) with IC50 values of 331, 257, and 187 nM, respectively. SJ-C1044 suppresses tumor cell proliferation by inhibiting kras activation and MEK-ERK phosphorylation. Additionally, it shows inhibition of VEGFR2, TIE2, and CSF1R, with IC50 values of 100, 23, and 235 nM respectively. The compound enhances the tumor immune microenvironment through inhibition of angiogenesis and modulation of macrophage function. SJ-C1044 is applicable for research in colorectal cancer.</p>Formula:C25H14F7N7OColore e forma:SolidPeso molecolare:561.41Protein kinase inhibitor 13
CAS:Protein kinase inhibitor 13 (Compound I-90) functions as a kinase inhibitor, specifically targeting kinases such as PIM-1, CDK-2, GSK-3, and SRC.Formula:C19H20FN5OSColore e forma:SolidPeso molecolare:385.458CGP062464
CAS:CGP062464 is an inhibitor of the tyrosine kinase c-Src, with an IC50 of less than 50 nM. It is utilized in research related to osteoporosis and tumor-induced hypercalcemia.Formula:C18H14N4Colore e forma:SolidPeso molecolare:286.331HER2-IN-8
CAS:HER2-IN-8 is an inhibitor of HER-2 that can be used in the study of cancer and inflammation-related diseases.Formula:C26H25F2N9O3Colore e forma:SolidPeso molecolare:549.53FGFR2/3-IN-2
CAS:<p>FGFR2/3-IN-2 (compound 10) is an orally active inhibitor targeting FGFR2 and FGFR3. It exhibits IC50 values of 3.7 nM for FGFR2 and 31.2 nM for FGFR3, with a pre-incubation time of 1 hour. FGFR2/3-IN-2 demonstrates selectivity over FGFR1/4 and other kinases, and does not cause diarrhea or increased serum phosphate in vivo. In the SNU-16 gastric cancer model, FGFR2/3-IN-2 can induce tumor stasis or regression.</p>Formula:C29H23FN6O3Colore e forma:SolidPeso molecolare:522.53EGFR-IN-159
CAS:<p>EGFR-IN-159 (compound 12) is a dihydropyrimidine and a potent EGFR inhibitor with an IC50 of 29.00 nM. It exhibits dose-dependent inhibition of EGFR and HER2. The compound shows cytotoxicity against MCF-7 breast cancer cells and Vero cells with IC50 values of 16.07 μg/mL and 35.98 μg/mL, respectively. EGFR-IN-159 does not cross the blood-brain barrier (BBB) and demonstrates significant anticancer activity.</p>Formula:C21H23N3O5Colore e forma:SolidPeso molecolare:397.424Gamendazole
CAS:Gamendazole is a novel drug candidate for male contraception. It has been shown to reduce fertility in male rats without affecting testosterone levels.Formula:C18H11Cl2F3N2O2Purezza:98%Colore e forma:SolidPeso molecolare:415.19EGFR-IN-149
CAS:EGFR-IN-149 (Compound 3-OH) is an EGFR inhibitor with an IC50 value of 0.42 nM.Formula:C16H15N3OSColore e forma:SolidPeso molecolare:297.375EGFR ligand-14
CAS:EGFRligand-14 serves as an EGFR ligand and is utilized in the synthesis of SJF-1521.Formula:C27H19ClFN3OColore e forma:SolidPeso molecolare:455.91Ifebemtinib tosylate
CAS:Ifebemtinib (tosylate) (BI-853520 (tosylate); IN-10018 (tosylate)) is a highly selective PTK2 kinase inhibitor with anti-tumor properties. It inhibits FAK autophosphorylation in prostate cancer cells and suppresses spheroid formation and in situ tumor growth in vivo. Ifebemtinib (tosylate) is applicable in cancer research, including studies on solid tumors, breast cancer, and malignant pleural mesothelioma.Formula:C35H36F4N6O7SColore e forma:SolidPeso molecolare:760.76CEP-7055
CAS:CEP-18770: oral proteasome inhibitor; blocks NF-kappaB; may cause cancer cell apoptosis; less toxic than bortezomib in normal cells.Formula:C32H35N3O4Colore e forma:SolidPeso molecolare:525.64
